Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.52254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Naveen Kumar Paramasivan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Autoantibodies, Autoimmunity, Limbic Encephalitis, Neuroblastoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech.
Abstract (Originalsprache)
Objective
To describe the phenotypes, oncological associations, biomarker profiles, and outcomes across different age groups in patients with ANNA1 (anti‐Hu) autoimmunity.
Methods
A retrospective review of patients with ANNA1‐IgG in serum/CSF between January 1, 2001, and December 31,2019 was performed. Patients were classified into three groups based on the age of symptom onset. Phage immunoprecipitation sequencing (PhIP‐Seq) and neurofilament light chain (NfL) measurements were done in patient sera/CSF with archived samples.
Results
Of 122 patients, 81 (66%), 20 (16%), and 21 (17%) patients belonged to older adults, young adults, and pediatric groups, respectively. Lung cancer and neuromuscular presentations were more common in older adults ( p < 0.001), while limbic encephalitis and neuroblastoma were more common in pediatric patients ( p < 0.005). Most young adults (75%) did not have cancer identified. Proportions of patients with a favorable response to immunotherapy were 20%, 30%, and 52% among older adults, young adults, and pediatric groups, respectively. PhIP‐Seq demonstrated significant enrichment for ELAVL4 peptides especially for amino acids 240–289, in the majority of samples evaluated (36/67, 54%). ZIC and SOX2 peptides were significantly enriched in those with central nervous system presentations. Serum NfL levels were elevated in patients with cancer and those with poor long‐term outcomes.
Interpretation
Young adults with ANNA1 autoimmunity phenotypically resembled older adults but rarely had an underlying cancer. Pediatric patients frequently presented with limbic encephalitis and neuroblastoma and often responded favorably to immunotherapy. Distinct antigenic signatures may underlie differences in clinical presentations. Serum NfL levels may be a biomarker of poor long‐term outcomes in ANNA1 autoimmunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Naveen Kumar Paramasivan, Haidara Kherbek, Anastasia Zekeridou, Andrew McKeon, Divyanshu Dubey
Förderung
- Genentech
Zitieren
APA
Paramasivan, N. K., Masoud, M., Karsten, C., Zahid, A., Kherbek, H., Zekeridou, A., Sista, S. R., Dasari, S., Knight, A. M., Mangioris, G., Mills, J. R., McKeon, A., Pittock, S. J., & Dubey, D. (2025). Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52254
Vancouver
Paramasivan NK, Masoud M, Karsten C, Zahid A, Kherbek H, Zekeridou A, et al. Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.52254
BibTeX
@article{Paramasivan2025,
author = {Paramasivan, Naveen Kumar and Masoud, Majed and Karsten, Carley and Zahid, Anza and Kherbek, Haidara and Zekeridou, Anastasia and Sista, Sri Raghav and Dasari, Surendra and Knight, Andrew M and Mangioris, Georgios and Mills, John R and McKeon, Andrew and Pittock, Sean J and Dubey, Divyanshu},
title = {Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.52254}
}
EUVIMED